The CNDP1 (CTG)5 Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration
Considering that the homozygous CNDP1 (CTG)5 genotype affords protection against diabetic nephropathy (DN) in female patients with type 2 diabetes, this study assessed if this association remains gender-specific when applying clinical inclusion criteria (CIC-DN) or biopsy proof (BP-DN). Additionally...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2017/9506730 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562666669867008 |
|---|---|
| author | Thomas Albrecht Shiqi Zhang Jana D. Braun Li Xia Angelica Rodriquez Jiedong Qiu Verena Peters Claus P. Schmitt Jacob van den Born Stephan J. L. Bakker Alexander Lammert Hannes Köppel Peter Schnuelle Bernhard K. Krämer Benito A. Yard Sibylle J. Hauske |
| author_facet | Thomas Albrecht Shiqi Zhang Jana D. Braun Li Xia Angelica Rodriquez Jiedong Qiu Verena Peters Claus P. Schmitt Jacob van den Born Stephan J. L. Bakker Alexander Lammert Hannes Köppel Peter Schnuelle Bernhard K. Krämer Benito A. Yard Sibylle J. Hauske |
| author_sort | Thomas Albrecht |
| collection | DOAJ |
| description | Considering that the homozygous CNDP1 (CTG)5 genotype affords protection against diabetic nephropathy (DN) in female patients with type 2 diabetes, this study assessed if this association remains gender-specific when applying clinical inclusion criteria (CIC-DN) or biopsy proof (BP-DN). Additionally, it assessed if the prevalence of the protective genotype changes with diabetes duration and time on hemodialysis and if this occurs in association with serum carnosinase (CN-1) activity. Whereas the distribution of the (CTG)5 homozygous genotype in the no-DN and CIC-DN patients was comparable, a lower frequency was found in the BP-DN patients, particularly in females. We observed a significant trend towards high frequencies of the (CTG)5 homozygous genotype with increased time on dialysis. This was also observed for diabetes duration but only reached significance when both (CTG)5 homo- and heterozygous patients were included. CN-1 activity negatively correlated with time on hemodialysis and was lower in (CTG)5 homozygous patients. The latter remained significant in female subjects after gender stratification. We confirm the association between the CNDP1 genotype and DN to be likely gender-specific. Although our data also suggest that (CTG)5 homozygous patients may have a survival advantage on dialysis and in diabetes, this hypothesis needs to be confirmed in a prospective cohort study. |
| format | Article |
| id | doaj-art-4401c6d5bd114c28a0b7fbf0e4c602fd |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-4401c6d5bd114c28a0b7fbf0e4c602fd2025-02-03T01:22:00ZengWileyJournal of Diabetes Research2314-67452314-67532017-01-01201710.1155/2017/95067309506730The CNDP1 (CTG)5 Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes DurationThomas Albrecht0Shiqi Zhang1Jana D. Braun2Li Xia3Angelica Rodriquez4Jiedong Qiu5Verena Peters6Claus P. Schmitt7Jacob van den Born8Stephan J. L. Bakker9Alexander Lammert10Hannes Köppel11Peter Schnuelle12Bernhard K. Krämer13Benito A. Yard14Sibylle J. Hauske15Fifth Medical Department (Nephrology/Endocrinology/Rheumatology), University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanyFifth Medical Department (Nephrology/Endocrinology/Rheumatology), University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanyFifth Medical Department (Nephrology/Endocrinology/Rheumatology), University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanyFifth Medical Department (Nephrology/Endocrinology/Rheumatology), University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanyFifth Medical Department (Nephrology/Endocrinology/Rheumatology), University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanyFifth Medical Department (Nephrology/Endocrinology/Rheumatology), University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanyCentre for Pediatric and Adolescent Medicine, University of Heidelberg, Heidelberg, GermanyCentre for Pediatric and Adolescent Medicine, University of Heidelberg, Heidelberg, GermanyNephrology, University Medical Center Groningen, University of Groningen, Groningen, NetherlandsNephrology, University Medical Center Groningen, University of Groningen, Groningen, NetherlandsFifth Medical Department (Nephrology/Endocrinology/Rheumatology), University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanyFifth Medical Department (Nephrology/Endocrinology/Rheumatology), University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanyFifth Medical Department (Nephrology/Endocrinology/Rheumatology), University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanyFifth Medical Department (Nephrology/Endocrinology/Rheumatology), University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanyFifth Medical Department (Nephrology/Endocrinology/Rheumatology), University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanyFifth Medical Department (Nephrology/Endocrinology/Rheumatology), University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanyConsidering that the homozygous CNDP1 (CTG)5 genotype affords protection against diabetic nephropathy (DN) in female patients with type 2 diabetes, this study assessed if this association remains gender-specific when applying clinical inclusion criteria (CIC-DN) or biopsy proof (BP-DN). Additionally, it assessed if the prevalence of the protective genotype changes with diabetes duration and time on hemodialysis and if this occurs in association with serum carnosinase (CN-1) activity. Whereas the distribution of the (CTG)5 homozygous genotype in the no-DN and CIC-DN patients was comparable, a lower frequency was found in the BP-DN patients, particularly in females. We observed a significant trend towards high frequencies of the (CTG)5 homozygous genotype with increased time on dialysis. This was also observed for diabetes duration but only reached significance when both (CTG)5 homo- and heterozygous patients were included. CN-1 activity negatively correlated with time on hemodialysis and was lower in (CTG)5 homozygous patients. The latter remained significant in female subjects after gender stratification. We confirm the association between the CNDP1 genotype and DN to be likely gender-specific. Although our data also suggest that (CTG)5 homozygous patients may have a survival advantage on dialysis and in diabetes, this hypothesis needs to be confirmed in a prospective cohort study.http://dx.doi.org/10.1155/2017/9506730 |
| spellingShingle | Thomas Albrecht Shiqi Zhang Jana D. Braun Li Xia Angelica Rodriquez Jiedong Qiu Verena Peters Claus P. Schmitt Jacob van den Born Stephan J. L. Bakker Alexander Lammert Hannes Köppel Peter Schnuelle Bernhard K. Krämer Benito A. Yard Sibylle J. Hauske The CNDP1 (CTG)5 Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration Journal of Diabetes Research |
| title | The CNDP1 (CTG)5 Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration |
| title_full | The CNDP1 (CTG)5 Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration |
| title_fullStr | The CNDP1 (CTG)5 Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration |
| title_full_unstemmed | The CNDP1 (CTG)5 Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration |
| title_short | The CNDP1 (CTG)5 Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration |
| title_sort | cndp1 ctg 5 polymorphism is associated with biopsy proven diabetic nephropathy time on hemodialysis and diabetes duration |
| url | http://dx.doi.org/10.1155/2017/9506730 |
| work_keys_str_mv | AT thomasalbrecht thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT shiqizhang thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT janadbraun thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT lixia thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT angelicarodriquez thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT jiedongqiu thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT verenapeters thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT clauspschmitt thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT jacobvandenborn thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT stephanjlbakker thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT alexanderlammert thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT hanneskoppel thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT peterschnuelle thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT bernhardkkramer thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT benitoayard thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT sibyllejhauske thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT thomasalbrecht cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT shiqizhang cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT janadbraun cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT lixia cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT angelicarodriquez cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT jiedongqiu cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT verenapeters cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT clauspschmitt cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT jacobvandenborn cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT stephanjlbakker cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT alexanderlammert cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT hanneskoppel cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT peterschnuelle cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT bernhardkkramer cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT benitoayard cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration AT sibyllejhauske cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration |